NewsPronto

 
The Times


.

ACN Newswire

Read more press releases from ACN Newswire here

Anticancer Agent Tazverik Tablets 200mg (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma

  • Written by ACN Newswire

image

TOKYO, Jun 23, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing approval for the EZH2 inhibitor "Tazverik Tablets 200 mg" (tazemetostat hydrobromide) in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not...

Read more: Anticancer Agent Tazverik Tablets 200mg (Tazemetostat Hydrobromide) Approved In Japan For EZH2...